BioInvent International AB (publ) focuses on the discovery and development of antibody-based drugs against cancer. The company's lead drug candidate is BI-1206, a human antibody targeting CD32b, an immunosuppressive protein that is expressed in patients with B-cell cancers. The BI-1206 drug is in Phase I/II clinical trials currently ongoing in patients with non-Hodgkin lymphoma and chronic lymphocytic leukaemia who are resistant to rituximab. The company has a collaboration agreement with Oncurious BV to develop TB-403, a humanized antibody directed against the PlGF protein, which is in Phase I/II clinical trials used for the treatment of patients with medulloblastoma; and with ThromboGenics to develop THR-317 that is in Phase I/II clinical trials used for the treatment of patients with diabetic macular edema. It is also developing immuno-modulatory antibodies, such as cancer-associated regulatory T cells and tumour-associated myeloid-derived suppressor cells. The company has a research collaboration and license agreement with Pfizer Inc. for the development of antibodies against tumour-associated myeloid cells. In addition, it has research collaborations with Bayer Pharma, Daiichi Sankyo, Mitsubishi Tanabe Pharma, Servier, Xoma, and Transgene, as well as University of Southampton, Cancer Research UK, Lund University, and Penn Medicine. The Company was founded in 1997 and is based in Lund, Sweden.
- Lund, Sweden
Primary Stock Exchange Listings